{
    "nct_id": "NCT04002401",
    "official_title": "A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)",
    "inclusion_criteria": "* Histologically confirmed large B-cell lymphoma\n* Chemotherapy-refractory disease, defined as one or more of the following:\n\n  * No response to first-line therapy (primary refractory disease)\n  * No response to second or greater lines of therapy OR\n  * Refractory after autologous stem cell transplant (ASCT)\n* At least 1 measureable lesion according to the Lugano Classification (Cheson 2014).\n* Individuals must have received adequate prior therapy, including at a minimum:\n\n  * Anti-CD20 monoclonal antibody\n  * An anthracycline-containing chemotherapy regimen\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate renal, hepatic, pulmonary, and cardiac function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known CD19 negative or CD20 negative tumor\n* History of Richter's transformation of Chronic Lymphocytic Leukemia (CLL)\n* Prior CAR therapy or other genetically modified T-cell therapy\n* Prior organ transplantation including prior allogeneic stem cell transplant (SCT)\n* Prior CD19 targeted therapy\n* Clinically significant infection or cardiopulmonary disease\n* Presence of any in-dwelling lines or drains (dedicated central venous access catheters allowed)\n* History or presence of central nervous system (CNS) lymphoma or nonmalignant CNS disorder or cerebrospinal fluid (CSF) malignant cells or brain metastases\n* History of autoimmune disease\n* History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last 6 months\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}